

Neuland Laboratories Limited

Sanali Info Park, 'A' Block,
Ground Floor, 8-2-120/113

Road No. 2, Banjara Hills
Hyderabad - 500 034.

Telangana, India.

Tel: 040 30211600 / 23551081

Fax: 040 30211602

Email: neuland@neulandlabs.com

www.neulandlabs.com

August 13, 2016

To
B S E Limited
Phiroze Jeejeebhoy Towers,
25th Floor, Dalal Street,
Mumbai - 400 001

To
The National Stock Exchange of
India Ltd
Exchange Plaza,
Bandra Kurla Complex
Bandra (E)
Mumbai - 400 001

Scrip Code: 524558

Scrip Code: NEULANLAB
Series: EQ

Dear Sirs,

Sub: Compliance with Regulation 47 (1) (b) of the SEBI Listing Regulations, 2015

Please find attached herewith copies of the newspaper publication of un-audited financial results for the quarter ended June 30, 2016, published in Financial Express and Andhra Prabha on August 13, 2016 for your reference.

Thanking you,

Yours faithfully,
For Neuland Laboratories Limited



Sarada Bhamidipati
Company Secretary

Encl : as above

Beijing, Aug 12: Ahead of foreign minister Wang Yi's visit to India, China's state-run media on Friday said the door for India's admission

China says NSG door not shut on India

into the NSG is "not tightly" closed and New Delhi should "fully comprehend" Bei-

jing's concerns over the disputed South China Sea. Terming that India and Chi-

na are partners not rivals, a commentary by state-run Xinhua news agency said "as

Beijing and New Delhi head season of intensive to diplomatic encounter could well define the

Govt doors open for all sections in Kashmir: PM

New Delhi, Aug 12: Prime Minister Narendra Modi on Friday said the doors of the national sentiment that there cannot be any compromise with the country's integrity.

"We are ready to address the grievances of all sections under the Constitution," Modi said. *PTI*

BF INVESTMENT LIMITED

CIN : L65993PN2009PLC134021
Regd. Off.: Mundhwa, Pune Cantonment,
Pune-411036 Tel: +91 20 66292550/2526
Email: bfinvestment@vsnl.net
Website: www.kalyanigroup.com/BFI.asp

NOTICE

Notice is hereby given that a meeting of the Board of Directors of the Company is scheduled on Saturday, August 20, 2016, to consider and take on record the Consolidated Audited Financial Results for the year ended March 31, 2016.

The above information is available on the Company's Website viz www.kalyanigroup.com/BFI.asp and also available on websites of Stock Exchanges viz www.nseindia.com and www.bseindia.com

For BF Investment Limited

Sd/-
Pune S. R. Kshirsagar
August 12, 2016 Company Secretary



Core-1, SCOPE Complex,
7, Institutional Area, Lodhi Road,
New Delhi-110 003 (India)
Phone: 011-24362200 Fax: 011-24364587

E-TENDER FOR SUPPLY OF PP BAGS

E-TENDER NO. MMTCL/AGRO/PP BAGS/2016-17/2. Dated: 12.08.2016
Closing at 1130 Hrs (IST) on 22.08.2016.

MMTCL invites offers for supply of PP Bags.

Copy of tender document can be obtained from Deputy General Manager (AGRO) or can be downloaded from our website: www.mmtclimited.gov.in & <http://eprocure.gov.in>

KOHINOOR FOODS LIMITED

Regd. Office: 201, Vipps Centre, Masjid Moth, G.K.-II, New Delhi-110048 (India) Ph: 011-29220330
Corporate Office: Pinnacle Business Tower, 10th Floor, Suraj Kund, Faridabad, Haryana - 121001
Ph. No. 0129-4242222, Fax No. 0129-4242233 E-mail: info@kohinoorfoods.in Visit us at: www.kohinoorfoods.in
CIN - L52110DL1989PLC037097

STATEMENT OF STANDALONE AUDITED FINANCIAL RESULT FOR THE QUARTER ENDED 30TH JUNE, 2016

(Rupees in Lacs except per share data)

Particulars	Quarter Ended 30th June, 2016 (Un-Audited)	Quarter Ended 31st March, 2016 (Audited)	Quarter Ended 30th June, 2015 (Un-Audited)	Year Ended 31.03.2016 (Audited)
Total Income from Operations (net)	27653	29810	28411	113090

NEULAND LABORATORIES LIMITED

(CIN : L85195TG1984PLC004393)

Regd. office: Sanali Info park, 'A' Block, Ground floor
8-2-120/113, Road No.2, Banjara Hills, Hyderabad-500034



UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30 JUNE 2016 (₹ in Lakhs)

Sl. No.	Particulars	Quarter Ended 30.06.2016 (Unaudited)	Quarter Ended 31.03.2016 (Audited)	Quarter Ended 30.06.2015 (Unaudited)	Year Ended 31.03.2016 (Audited)
1	Income from operations				
	(a) Net Sales / Income from Operations	14,558.44	12,684.53	11,912.48	48,576.71
	(b) Other Operating Income	418.16	819.23	459.50	2,420.30
	Total Income from Operations (Net)	14,976.60	13,503.76	12,371.98	50,997.01
2	Expenses				
	(a) Cost of Materials consumed	6,970.72	6,577.83	6,700.39	25,956.67
	(b) Changes in inventories of finished goods and work-in-progress	79.14	(526.65)	(375.35)	(611.18)
	(c) Employee benefits expense	1,666.16	1,497.15	1,527.64	5,989.23
	(d) Depreciation and amortization expense	436.07	411.16	380.20	1,574.26
	(e) Manufacturing expenses	1,462.10	1,608.90	1,225.70	5,284.20
	(f) Sales promotion expenses including sales commission	1,512.20	1,353.31	151.17	2,039.90
	(g) Other expenses	830.05	974.13	1,031.84	4,351.22
	Total expenses	12,956.44	11,895.83	10,641.59	44,584.30
3	Profit from operations before other income, finance costs and exceptional items (1-2)	2,020.16	1,607.93	1,730.39	6,412.71
4	Other Income	48.70	73.10	52.86	161.91
5	Profit from ordinary activities before finance costs and exceptional items (3+4)	2,068.86	1,681.03	1,783.25	6,574.62
6	Finance Costs	609.68	528.29	654.10	2,446.60
7	Profit from ordinary activities after finance costs but before exceptional items (5-6)	1,459.18	1,152.74	1,129.15	4,128.02
8	Exceptional Items	-	-	-	-
9	Profit from ordinary activities before tax (7-8)	1,459.18	1,152.74	1,129.15	4,128.02
10	Tax expense	488.05	489.38	399.09	1,486.54
11	Net profit from ordinary activities after tax (9-10)	971.13	663.36	730.06	2,641.48
12	Extraordinary items	-	-	-	-
13	Net profit for the period (11-12)	971.13	663.36	730.06	2,641.48
14	Paid-up Equity Share Capital (Face value of ₹10 per share)	895.39	895.39	895.39	895.39
15	Reserves excluding Revaluation Reserve as per balance sheet of previous accounting year	-	-	-	17,437.92
16.i	Earnings per share (before extraordinary items) (of ₹10 each) (In absolute ₹)				
	(a) Basic (not annualized)	10.93	7.46	8.22	29.73
	(b) Diluted (not annualized)	10.93	7.46	8.22	29.73
16.ii	Earnings per share (after extraordinary items) (of ₹10 each) (In absolute ₹)				
	(a) Basic (not annualized)	10.93	7.46	8.22	29.73
	(b) Diluted (not annualized)	10.93	7.46	8.22	29.73

NOTES:

- The above unaudited financial results have been reviewed by the Audit Committee at their meeting held on August 11, 2016, and approved and taken on record at the Board of Directors meeting held on August 12, 2016.
- EPS for quarters are not annualized.
- The Company's operations are predominantly related to the manufacture of Active Pharmaceutical Ingredients (API). As such there is only one primary reportable segment as per Accounting Standard - AS 17 "Segment Reporting".
- The Company has entered into a Joint Development Agreement (JDA) with Phoenix Embassy techno Zone Private Limited for development of the land owned by the Company at Nanakramguda, Hyderabad. In terms of the said JDA, the Company would be entitled to receive approximately 23% share of the total saleable area of the proposed project, which would be duly determined on the basis of an approval of the building plans by the authorities concerned.
- Previous period figures have been re-grouped/reclassified wherever necessary, to confirm to the current period's classification.

Place: Hyderabad
Date: August 12, 2016

By Order of the Board
For Neuland Laboratories Limited
Sd/-
Dr.D.R.Rao
Chairman & Managing Director
(DIN 00107737)

RAJPUTANA IN

REGISTERED OFFICE

BAGUI

Statement of U

for th

Sl. No.	Particulars
1	Total income from Operations
2	Net Profit / (Loss) from ordinary activities
3	Paid-up equity share capital (Face Value of ₹10/- each)
4	Reserve & Surplus
5	Earnings Per Share (not annualized)

Place: Kolkata.

Date: August 11, 2016



CIN: L27104

Regd. Office: 115-116, G.I.

Ph. 079

Website: www.welco

Statement of Unaudited

Sl. No.	Particulars
1	Total income from operations
2	Net Profit / (Loss) for the period
3	Net Profit / (Loss) for the period (after Exceptional and/or Extraordinary items)
4	Net Profit / (Loss) for the period (after Exceptional and/or Extraordinary items) (for continuing and discontinued operations)
5	Total Comprehensive Income
6	Equity Share Capital
7	Reserves (excluding Reserve shown in the Audited Balance Sheet of the previous year)
8	Earnings Per Share (EPS) (for continuing and discontinued operations)

Notes: (i) Statement of reclassified profit reported under previous period as under:

Particulars
Net Profit after Tax as per Add: Impact of Ind AS 19 accounted OCI
Net Profit after Tax before Other Comprehensive Income
Total Comprehensive Income
(ii) The above is an extract of the financial statements for the months ended June 30, 2016, as per the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The Full format of the Financial Statements are available on the stock exchange website and the Company's website (www.welco)

Place: Ahmedabad
Date: 12th August, 2016

[illegible]

 CUBEX TUBINGS LTD. (An ISO 9001:2008 CERTIFIED COMPANY) CIN L 27109 Regd. Office: 1-7-27 to 34, 2nd Floor, Shyam Towers, S.D.Road, Sec-bad - 500008 (Hyderabad)	906.30	906.30	906.30
	37,545.05	25,621.29	37,545.05
STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR THE QUARTER	11.10	10.07	35.07
	11.10	10.07	35.07

Particulars	UN AUDITED	AUDITED	అదనపు సమాచారం దిగువ ఇవ్వబడినది. (రూ. లక్షలలో)	ముగిసిన త్రైమాసికం	ముగిసిన సంవత్సరం
	Quarter ended	Year			
	30-06-2016	31-03-2016			
Total income from operations (net)	842.01	5.0			
Net Profit/(Loss) from ordinary activities after tax	12.05				
Net Profit /(Loss) for the period after tax (after Extraordinary items)	12.05				
Equity Share Capital	1,431.89	1.4			
Reserves(excluding revaluation reserves as per Balance Sheet of previous year)	4,221.87	4.2			
Earnings per share (before extraordinary items) (of Rs10/- each)	—				
Basic:	0.08				
Diluted:	0.08				
Earnings per share (after extraordinary items) (of Rs10/- each)	—				
Basic:	0.08				
Diluted:	0.08				

Note:

1. The above is an extract of detailed format of Quarterly / Annual Financial Results under Regulation 33 of the SEBI (Listing and Other Disclosure Requirements) Regulations, 2015. The Quarterly / Annual Financial Results are available on stock exchange websites and www.nseindia.com respectively.

**For and on
CUBEX**

Place: Hyderabad
Date: 12-08-2016

Sd/-
D/
MANA

మెస్సర్స్ అవంతి ఫీడ్స్ రిమిమిడ్ కొరకు
ఎ.ఇంద్ర కుమార్
ప్లైస్ & మేనేజింగ్ డైరెక్టర్
దీనింట్: 00190168

NEULAND LABORATORIES LIMITED

(CIN : L85195TG1984PLC004393)

Regd. office: Sanali Info park, 'A' Block, Ground floor
8-2-120/113, Road No.2, Banjara Hills, Hyderabad-500034

UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30 JUNE 2016

(₹ in Lakhs)

Sl. No.	Particulars	Quarter Ended 30.06.2016	Quarter Ended 31.03.2016	Quarter Ended 30.06.2015	Year Ended 31.03.2016
		(Unaudited)	(Audited)	(Unaudited)	(Audited)
1	Income from operations				
	(a) Net Sales / Income from Operations	14,558.44	12,684.53	11,912.48	48,576.71
	(b) Other Operating Income	418.16	819.23	459.50	2,420.30
	Total Income from Operations (Net)	14,976.60	13,503.76	12,371.98	50,997.01
2	Expenses				
	(a) Cost of Materials consumed	6,970.72	6,577.83	6,700.39	25,956.67
	(b) Changes in inventories of finished goods and work-in-progress	79.14	(526.65)	(375.35)	(611.18)
	(c) Employee benefits expense	1,666.16	1,497.15	1,527.64	5,989.23
	(d) Depreciation and amortization expense	436.07	411.16	380.20	1,574.26
	(e) Manufacturing expenses	1,462.10	1,608.90	1,225.70	5,284.20
	(f) Sales promotion expenses including sales commission	1,512.20	1,353.31	151.17	2,039.90
	(g) Other expenses	830.05	974.13	1,031.84	4,351.22
	Total expenses	12,956.44	11,895.83	10,641.59	44,584.30
3	Profit from operations before other income, finance costs and exceptional items (1-2)	2,020.16	1,607.93	1,730.39	6,412.71
4	Other Income	48.70	73.10	52.86	161.91
5	Profit from ordinary activities before finance costs and exceptional items (3+4)	2,068.86	1,681.03	1,783.25	6,574.62
6	Finance Costs	609.68	528.29	654.10	2,446.60
7	Profit from ordinary activities after finance costs but before exceptional items (5-6)	1,459.18	1,152.74	1,129.15	4,128.02
8	Exceptional Items	-	-	-	-
9	Profit from ordinary activities before tax (7-8)	1,459.18	1,152.74	1,129.15	4,128.02
10	Tax expense	488.05	489.38	399.09	1,486.54
11	Net profit from ordinary activities after tax (9-10)	971.13	663.36	730.06	2,641.48
12	Extraordinary items	-	-	-	-
13	Net profit for the period (11-12)	971.13	663.36	730.06	2,641.48
14	Paid-up Equity Share Capital (Face value of ₹10 per share)	895.39	895.39	895.39	895.39
15	Reserves excluding Revaluation Reserve as per balance sheet of previous accounting year	-	-	-	17,437.92
16.i	Earnings per share (before extraordinary items) (of ₹10 each) (In absolute ₹)				
	(a) Basic (not annualized)	10.93	7.46	8.22	29.73
	(b) Diluted (not annualized)	10.93	7.46	8.22	29.73
16.ii	Earnings per share (after extraordinary items) (of ₹10 each) (In absolute ₹)				
	(a) Basic (not annualized)	10.93	7.46	8.22	29.73
	(b) Diluted (not annualized)	10.93	7.46	8.22	29.73

See accompanying notes to the financial results

NOTES:

1 The above unaudited financial results have been reviewed by the Audit Committee at their meeting held on August 11, 2016, and approved and taken on record at the Board of Directors meeting held on August 12, 2016.

2 EPS for quarters are not annualized

3 The Company's operations are predominantly related to the manufacture of Active Pharmaceutical Ingredients (API). As such there is only one primary reportable segment as per Accounting Standard - AS 17 "Segment Reporting".

4 The Company has entered into a Joint Development Agreement(JDA) with Phoenix Embassy techno Zone Private Limited for development of the land owned by the Company at Nanakramguda, Hyderabad. In terms of the said JDA, the Company would be entitled to receive approximately 23% share of the total saleable area of the proposed project, which would be duly determined on the basis of an approval of the building plans by the authorities concerned.

5 Previous period figures have been re-grouped/reclassified wherever necessary, to confirm to the current period's classification.

By Order of the Board
For Neuland Laboratories Limited
Sd/-

Place: Hyderabad
Date: August 12, 2016

Dr. D. R. Rao
Chairman & Managing Director
(DIN 00107737)